{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:48Z","timestamp":1790468808242,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1038\/ncponc0930","type":"journal-article","created":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T07:40:57Z","timestamp":1190878857000},"page":"578-590","source":"Crossref","is-referenced-by-count":93,"title":["Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome"],"prefix":"10.1038","volume":"4","author":[{"given":"Dimitrios H","family":"Roukos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc0930_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y  et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66\u201371","journal-title":"Science"},{"key":"BFncponc0930_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R  et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789\u2013792","journal-title":"Nature"},{"key":"BFncponc0930_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod SA and Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665\u2013676","journal-title":"Nat Rev Cancer"},{"key":"BFncponc0930_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1056\/NEJMra012284","volume":"348","author":"R Wooster","year":"2003","unstructured":"Wooster R and Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348: 2339\u20132347","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171\u2013182","journal-title":"Cell"},{"issue":"8 Suppl","key":"BFncponc0930_CR6","first-page":"104","volume":"40","author":"ML Brown","year":"2002","unstructured":"Brown ML  et al. (2002) Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40: (8 Suppl) IV: 104\u2013117","journal-title":"Med Care"},{"key":"BFncponc0930_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","volume":"144","author":"K Anderson","year":"2006","unstructured":"Anderson K  et al. (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144: 397\u2013406","journal-title":"Ann Intern Med"},{"key":"BFncponc0930_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H  et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917\u2013921","journal-title":"Nature"},{"key":"BFncponc0930_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE  et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913\u2013917","journal-title":"Nature"},{"key":"BFncponc0930_CR10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F  et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137\u20132150","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A  et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43\u201366","journal-title":"CA Cancer J Clin"},{"key":"BFncponc0930_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1245\/ASO.2004.09.910","volume":"11","author":"NJ Agnantis","year":"2004","unstructured":"Agnantis NJ  et al. (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11: 1030\u20131034","journal-title":"Ann Surg Oncol"},{"key":"BFncponc0930_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","volume":"143","author":"HD Nelson","year":"2005","unstructured":"Nelson HD  et al. (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 143: 362\u2013379","journal-title":"Ann Intern Med"},{"key":"BFncponc0930_CR14","doi-asserted-by":"crossref","unstructured":"Kadouri L  et al. (2007) Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations. J Med Genet [doi: 10.1136\/jmg.2006.048173]","DOI":"10.1136\/jmg.2006.048173"},{"key":"BFncponc0930_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1200\/JCO.2005.10.035","volume":"23","author":"SA Narod","year":"2005","unstructured":"Narod SA and Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23: 1656\u20131663","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/87876","volume":"7","author":"KL Nathanson","year":"2001","unstructured":"Nathanson KL  et al. (2001) Breast cancer genetics: what we know and what we need. Nat Med 7: 552\u2013556","journal-title":"Nat Med"},{"key":"BFncponc0930_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PD Pharoah","year":"2002","unstructured":"Pharoah PD  et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33\u201336","journal-title":"Nat Genet"},{"key":"BFncponc0930_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/gcc.20354","volume":"45","author":"P Smith","year":"2006","unstructured":"Smith P  et al. (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45: 646\u2013655","journal-title":"Genes Chromosomes Cancer"},{"key":"BFncponc0930_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H  et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55\u201359","journal-title":"Nat Genet"},{"key":"BFncponc0930_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","volume":"295","author":"T Walsh","year":"2006","unstructured":"Walsh T  et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379\u20131388","journal-title":"JAMA"},{"key":"BFncponc0930_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","volume":"25","author":"MK Schmidt","year":"2007","unstructured":"Schmidt MK  et al. (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25: 64\u201369","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1200\/JCO.2005.05.5160","volume":"25","author":"M Weischer","year":"2007","unstructured":"Weischer M  et al. (2007) Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 25: 57\u201363","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMp068079","volume":"355","author":"AJ Wolfberg","year":"2006","unstructured":"Wolfberg AJ (2006) Genes on the Web\u2014direct-to-consumer marketing of genetic testing. N Engl J Med 355: 543\u2013545","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMp068136","volume":"355","author":"PA Roche","year":"2006","unstructured":"Roche PA and Annas GJ (2006) DNA testing, banking, and genetic privacy. N Engl J Med 355: 545\u2013546","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jmg.2006.043091","volume":"44","author":"A Smith","year":"2007","unstructured":"Smith A  et al. (2007) Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 44: 10\u201315","journal-title":"J Med Genet"},{"key":"BFncponc0930_CR26","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143: 355\u2013361","DOI":"10.7326\/0003-4819-143-5-200509060-00011"},{"key":"BFncponc0930_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A  et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"BFncponc0930_CR28","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.2005.03.7259","volume":"24","author":"S van Dijk","year":"2006","unstructured":"van Dijk S  et al. (2006) Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 24: 3672\u20133677","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ejca.2003.10.028","volume":"40","author":"P Sauven","year":"2004","unstructured":"Sauven P (2004) Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer 40: 653\u2013665","journal-title":"Eur J Cancer"},{"key":"BFncponc0930_CR30","unstructured":"National Comprehensive Cancer Network (2007) Clinical Practice Guidelines in Oncology\u2014version 1.2007. Hereditary Breast and\/or Ovarian Genetic Assessment. [\n                    http:\/\/www.nccn.com\n                    \n                  ] (accessed 03.24.2007 at \n                    www.nccn.org\n                    \n                  )"},{"key":"BFncponc0930_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2005.02.2368","volume":"24","author":"CH Barcenas","year":"2006","unstructured":"Barcenas CH  et al. (2006) Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24: 354\u2013360","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC  et al. (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643\u2013646","journal-title":"Science"},{"key":"BFncponc0930_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1126\/science.1091465","volume":"302","author":"E Levy-Lahad","year":"2003","unstructured":"Levy-Lahad E and Plon SE (2003) Cancer. A risky business\u2014assessing breast cancer risk. Science 302: 574\u2013575","journal-title":"Science"},{"key":"BFncponc0930_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF02574474","volume":"9","author":"DH Roukos","year":"2002","unstructured":"Roukos DH  et al. (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9: 607\u2013609","journal-title":"Ann Surg Oncol"},{"key":"BFncponc0930_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/jnci\/95.13.941","volume":"95","author":"HM Klaren","year":"2003","unstructured":"Klaren HM  et al. (2003) Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 95: 941\u2013947","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H  et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159\u2013164","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR  et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22: 1055\u20131062","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC  et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77\u201384","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC  et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93: 1633\u20131637","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.2006.07.3890","volume":"25","author":"KP Tercyak","year":"2007","unstructured":"Tercyak KP  et al. (2007) Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1\/2 gene testing. J Clin Oncol 25: 285\u2013291","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR41","doi-asserted-by":"publisher","first-page":"7772","DOI":"10.1200\/JCO.2005.07.906","volume":"23","author":"WS Rubinstein","year":"2005","unstructured":"Rubinstein WS (2005) Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. J Clin Oncol 23: 7772\u20137774","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR42","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR  et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475\u20131479","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR43","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A  et al. (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23: 7491\u20137496","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR44","unstructured":"Struewing JP  et al. (1995) Prophylactic oophorectomy in inherited breast\/ovarian cancer families. J Natl Cancer Inst Monogr 33\u201335"},{"key":"BFncponc0930_CR45","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR  et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616\u20131622","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","volume":"7","author":"SM Domchek","year":"2006","unstructured":"Domchek SM  et al. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7: 223\u2013229","journal-title":"Lancet Oncol"},{"key":"BFncponc0930_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1470-2045(06)70589-7","volume":"7","author":"CT Brekelmans","year":"2006","unstructured":"Brekelmans CT and Seynaeve C (2006) Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation? Lancet Oncol 7: 191\u2013193","journal-title":"Lancet Oncol"},{"key":"BFncponc0930_CR48","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND  et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609\u20131615","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A  et al. (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296: 185\u2013192","journal-title":"JAMA"},{"key":"BFncponc0930_CR50","first-page":"941","volume":"9","author":"DH Roukos","year":"2002","unstructured":"Roukos DH  et al. (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9: 941\u2013943","journal-title":"Ann Surg Oncol"},{"key":"BFncponc0930_CR51","doi-asserted-by":"publisher","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","volume":"23","author":"JL Kramer","year":"2005","unstructured":"Kramer JL  et al. (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23: 8629\u20138635","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR52","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2004.06.090","volume":"22","author":"K Armstrong","year":"2004","unstructured":"Armstrong K  et al. (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1\/2 mutations: a decision analysis. J Clin Oncol 22: 1045\u20131054","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","volume":"8","author":"JR McLaughlin","year":"2007","unstructured":"McLaughlin JR  et al. (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8: 26\u201334","journal-title":"Lancet Oncol"},{"key":"BFncponc0930_CR54","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1038\/sj.onc.1209870","volume":"25","author":"SA Narod","year":"2006","unstructured":"Narod SA (2006) Modifiers of risk of hereditary breast cancer. Oncogene 25: 5832\u20135836","journal-title":"Oncogene"},{"key":"BFncponc0930_CR55","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS  et al. (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365\u20131372","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/annonc\/mdg030","volume":"14","author":"G Pichert","year":"2003","unstructured":"Pichert G  et al. (2003) Evidence-based management options for women at increased breast\/ovarian cancer risk. Ann Oncol 14: 9\u201319","journal-title":"Ann Oncol"},{"key":"BFncponc0930_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3322\/canjclin.53.3.141","volume":"53","author":"RA Smith","year":"2003","unstructured":"Smith RA  et al. (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53: 141\u2013169","journal-title":"CA Cancer J Clin"},{"key":"BFncponc0930_CR58","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/cncr.20221","volume":"100","author":"IK Komenaka","year":"2004","unstructured":"Komenaka IK  et al. (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100: 2079\u20132083","journal-title":"Cancer"},{"key":"BFncponc0930_CR59","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa031759","volume":"351","author":"M Kriege","year":"2004","unstructured":"Kriege M  et al. (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351: 427\u2013437","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.2006.07.4922","volume":"25","author":"JB Madalinska","year":"2007","unstructured":"Madalinska JB  et al. (2007) Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1\/2 mutation carriers. J Clin Oncol 25: 301\u2013307","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/bmj.306.6884.1025","volume":"306","author":"TH Bourne","year":"1993","unstructured":"Bourne TH  et al. (1993) Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306: 1025\u20131029","journal-title":"BMJ"},{"key":"BFncponc0930_CR62","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519\u20132529","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR63","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1200\/JCO.2004.07.179","volume":"22","author":"R Hogg","year":"2004","unstructured":"Hogg R and Friedlander M (2004) Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22: 1315\u20131327","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/bcr1287","volume":"7","author":"R Schiff","year":"2005","unstructured":"Schiff R and Osborne CK (2005) Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 7: 205\u2013211","journal-title":"Breast Cancer Res"},{"key":"BFncponc0930_CR65","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B  et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR66","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B  et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652\u20131662","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR67","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J  et al. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296\u2013300","journal-title":"Lancet"},{"key":"BFncponc0930_CR68","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC  et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251\u20132256","journal-title":"JAMA"},{"key":"BFncponc0930_CR69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.canlet.2006.05.003","volume":"247","author":"Z Kote-Jarai","year":"2007","unstructured":"Kote-Jarai Z  et al. (2007) BRCA1\/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett 247: 259\u2013265","journal-title":"Cancer Lett"},{"key":"BFncponc0930_CR70","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bjc.6603042","volume":"94","author":"M Bramley","year":"2006","unstructured":"Bramley M  et al. (2006) Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer 94: 1021\u20131028","journal-title":"Br J Cancer"},{"key":"BFncponc0930_CR71","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdi302","volume":"16","author":"H Gogas","year":"2005","unstructured":"Gogas H  et al. (2005) Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting? Ann Oncol 16: 1861\u20131866","journal-title":"Ann Oncol"},{"key":"BFncponc0930_CR72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2005.08.028","volume":"23","author":"BK Dunn","year":"2005","unstructured":"Dunn BK  et al. (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23: 357\u2013367","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR73","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1196\/annals.1386.010","volume":"1089","author":"VG Vogel","year":"2006","unstructured":"Vogel VG (2006) Recent results from clinical trials using SERMs to reduce the risk of breast cancer. Ann N Y Acad Sci 1089: 127\u2013142","journal-title":"Ann N Y Acad Sci"},{"key":"BFncponc0930_CR74","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG  et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727\u20132741","journal-title":"JAMA"},{"key":"BFncponc0930_CR75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/jnci\/djk062","volume":"99","author":"VC Jordan","year":"2007","unstructured":"Jordan VC (2007) SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 99: 350\u2013356","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR76","doi-asserted-by":"publisher","first-page":"372S","DOI":"10.1158\/1078-0432.CCR-031210","volume":"10","author":"PE Goss","year":"2004","unstructured":"Goss PE and Strasser-Weippl K (2004) Prevention strategies with aromatase inhibitors. Clin Cancer Res 10: 372S\u2013379S","journal-title":"Clin Cancer Res"},{"key":"BFncponc0930_CR77","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0140-6736(06)68594-2","volume":"367","author":"RM O'Regan","year":"2006","unstructured":"O'Regan RM (2006) Chemoprevention of breast cancer. Lancet 367: 1382\u20131383","journal-title":"Lancet"},{"key":"BFncponc0930_CR78","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jnci\/djj357","volume":"98","author":"D Mauri","year":"2006","unstructured":"Mauri D  et al. (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98: 1285\u20131291","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"BFncponc0930_CR79","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1525-1438.2006.00685.x","volume":"16","author":"PE Lonning","year":"2006","unstructured":"Lonning PE (2006) Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 16 (Suppl 2): 518\u2013520","journal-title":"Int J Gynecol Cancer"},{"key":"BFncponc0930_CR80","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1200\/JCO.2006.07.5382","volume":"24","author":"AJ Chien","year":"2006","unstructured":"Chien AJ and Goss PE (2006) Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24: 5305\u20135312","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR81","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1634\/theoncologist.11-6-553","volume":"11","author":"K Altundag","year":"2006","unstructured":"Altundag K and Ibrahim NK (2006) Aromatase inhibitors in breast cancer: an overview. Oncologist 11: 553\u2013562","journal-title":"Oncologist"},{"key":"BFncponc0930_CR82","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","volume":"94","author":"SA Narod","year":"2002","unstructured":"Narod SA  et al. (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773\u20131779","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0930_CR83","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","volume":"91","author":"AS Whittemore","year":"2004","unstructured":"Whittemore AS  et al. (2004) Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91: 1911\u20131915","journal-title":"Br J Cancer"},{"key":"BFncponc0930_CR84","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR  et al. (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23: 7804\u20137810","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR85","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","volume":"365","author":"V Beral","year":"2005","unstructured":"Beral V  et al. (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543\u20131551","journal-title":"Lancet"},{"key":"BFncponc0930_CR86","doi-asserted-by":"publisher","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","volume":"23","author":"JB Madalinska","year":"2005","unstructured":"Madalinska JB  et al. (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23: 6890\u20136898","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR87","first-page":"3409","volume":"56","author":"DB Berman","year":"1996","unstructured":"Berman DB  et al. (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56: 3409\u20133414","journal-title":"Cancer Res"},{"key":"BFncponc0930_CR88","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00125817-200209000-00006","volume":"4","author":"A Bish","year":"2002","unstructured":"Bish A  et al. (2002) No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches. Genet Med 4: 353\u2013358","journal-title":"Genet Med"},{"key":"BFncponc0930_CR89","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","volume":"16","author":"A Goldhirsch","year":"2005","unstructured":"Goldhirsch A  et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569\u20131583","journal-title":"Ann Oncol"},{"key":"BFncponc0930_CR90","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce LJ  et al. (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J Clin Oncol 24: 2437\u20132443","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR91","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1054\/bjoc.2001.2103","volume":"85","author":"GH de Bock","year":"2001","unstructured":"de Bock GH  et al. (2001) Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 85: 1347\u20131350","journal-title":"Br J Cancer"},{"key":"BFncponc0930_CR92","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR  et al. (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310\u20132318","journal-title":"J Clin Oncol"},{"key":"BFncponc0930_CR93","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2407-5-70","volume":"5","author":"A Veronesi","year":"2005","unstructured":"Veronesi A  et al. (2005) Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 5: 70","journal-title":"BMC Cancer"},{"key":"BFncponc0930_CR94","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I Cass","year":"2003","unstructured":"Cass I  et al. (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187\u20132195","journal-title":"Cancer"},{"key":"BFncponc0930_CR95","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMcibr052331","volume":"353","author":"LC Brody","year":"2005","unstructured":"Brody LC (2005) Treating cancer by targeting a weakness. N Engl J Med 353: 949\u2013950","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR96","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-05-1186","volume":"65","author":"T Hay","year":"2005","unstructured":"Hay T  et al. (2005) Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 65: 10145\u201310148","journal-title":"Cancer Res"},{"key":"BFncponc0930_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.coph.2006.02.004","volume":"6","author":"ER Plummer","year":"2006","unstructured":"Plummer ER (2006) Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6: 364\u2013368","journal-title":"Curr Opin Pharmacol"},{"key":"BFncponc0930_CR98","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver MJ  et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999\u20132009","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR99","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.1073\/pnas.1732912100","volume":"100","author":"C Sotiriou","year":"2003","unstructured":"Sotiriou C  et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393\u201310398","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc0930_CR100","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","volume":"25","author":"NC Turner","year":"2006","unstructured":"Turner NC and Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846\u20135853","journal-title":"Oncogene"},{"key":"BFncponc0930_CR101","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator S  et al. (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235\u2013244","journal-title":"Lancet Oncol"},{"key":"BFncponc0930_CR102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/01.pas.0000213351.49767.0f","volume":"31","author":"AL Bane","year":"2007","unstructured":"Bane AL  et al. (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31: 121\u2013128","journal-title":"Am J Surg Pathol"},{"key":"BFncponc0930_CR103","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S  et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817\u20132826","journal-title":"N Engl J Med"},{"key":"BFncponc0930_CR104","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4161\/cbt.6.3.3994","volume":"6","author":"DH Roukos","year":"2007","unstructured":"Roukos DH  et al. (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6: 308\u2013312","journal-title":"Cancer Biol Ther"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0930","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T16:48:58Z","timestamp":1684428538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":104,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["BFncponc0930"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0930","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091180.544580","asserted-by":"object"}]},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}